• Eisai, Merck Announce FDA Approval of Lenvima fiercepharma
    August 20, 2018
    Eisai and Merck announced the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor Lenvima (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).
PharmaSources Customer Service